| Prostaglandin E2 EP receptors as therapeutic targets in breast cancer J Reader, D Holt, A Fulton Cancer and Metastasis Reviews 30 (3), 449-463, 2011 | 181 | 2011 |
| A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis X Ma, D Holt, N Kundu, J Reader, O Goloubeva, Y Take, AM Fulton Oncoimmunology 2 (1), e22647, 2013 | 121 | 2013 |
| Multiple myeloma patients with CKS1B gene amplification have a shorter progression‐free survival post‐autologous stem cell transplantation H Chang, X Qi, Y Trieu, W Xu, JC Reader, Y Ning, D Reece British journal of haematology 135 (4), 486-491, 2006 | 110 | 2006 |
| Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response BP Rickard, C Conrad, AJ Sorrin, MK Ruhi, JC Reader, SA Huang, ... Cancers 13 (17), 4318, 2021 | 106 | 2021 |
| Eicosanoids in Cancer: Prostaglandin E2 Receptor 4 in Cancer Therapeutics and Immunotherapy MM Ching, J Reader, AM Fulton Frontiers in pharmacology 11, 819, 2020 | 102 | 2020 |
| Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties N Kundu, X Ma, T Kochel, O Goloubeva, P Staats, K Thompson, S Martin, ... Breast cancer research and treatment 143 (1), 19-31, 2014 | 80 | 2014 |
| A novel NUP98-PHF23 fusion resulting from a cryptic translocation t (11; 17)(p15; p13) in acute myeloid leukemia JC Reader, JS Meekins, I Gojo, Y Ning Leukemia 21 (4), 842-844, 2007 | 75 | 2007 |
| Review of immune therapies targeting ovarian cancer CA Fan, J Reader, DM Roque Current treatment options in oncology 19 (12), 1-21, 2018 | 69 | 2018 |
| Prostaglandin E Receptor EP1 Suppresses Breast Cancer Metastasis and Is Linked to Survival Differences and Cancer DisparitiesEP1 Is a Metastasis Suppressor X Ma, N Kundu, OB Ioffe, O Goloubeva, R Konger, C Baquet, P Gimotty, ... Molecular Cancer Research 8 (10), 1310-1318, 2010 | 54 | 2010 |
| Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer TJ Kochel, JC Reader, X Ma, N Kundu, AM Fulton Oncotarget 8 (4), 6540, 2017 | 53 | 2017 |
| Activation of a novel palmitoyltransferase ZDHHC14 in acute biphenotypic leukemia and subsets of acute myeloid leukemia L Yu, JC Reader, C Chen, XF Zhao, JS Ha, C Lee, T York, I Gojo, ... Leukemia 25 (2), 367-371, 2011 | 43 | 2011 |
| Divergent roles of CXCR3 isoforms in promoting cancer stem-like cell survival and metastasis Y Li, JC Reader, X Ma, N Kundu, T Kochel, AM Fulton Breast cancer research and treatment 149 (2), 403-415, 2015 | 41 | 2015 |
| Analysis of 6q deletion in Waldenstrom macroglobulinemia H Chang, X Qi, W Xu, JC Reader, Y Ning European journal of haematology 79 (3), 244-247, 2007 | 30 | 2007 |
| Combined inhibition of IL‑6 and IL‑8 pathways suppresses ovarian cancer cell viability and migration and tumor growth R Zhang, DM Roque, J Reader, J Lin International Journal of Oncology 60 (5), 1-9, 2022 | 22 | 2022 |
| The chemokine receptor CXCR3 isoform B drives breast cancer stem cells N Kundu, X Ma, R Brox, X Fan, T Kochel, J Reader, N Tschammer, ... Breast Cancer: Basic and Clinical Research 13, 1178223419873628, 2019 | 22 | 2019 |
| EP4 and Class III β-Tubulin expression in uterine smooth muscle tumors: implications for prognosis and treatment J Reader, AK Harper, T Legesse, PN Staats, O Goloubeva, GG Rao, ... Cancers 11 (10), 1590, 2019 | 19 | 2019 |
| Regulation of differentiation by a PHD domain in the NUP98-PHF23 fusion protein JC Reader, Q Leng, FV Rassool, Y Ning Leukemia research 34 (8), 1094-1097, 2010 | 14 | 2010 |
| REL-positive double minute chromosomes in follicular lymphoma JC Reader, XF Zhao, MS Butler, AP Rapoport, Y Ning Leukemia 20 (9), 1624-1626, 2006 | 14 | 2006 |
| The role of eicosanoids in gynecological malignancies PG Smith, D Roque, MM Ching, A Fulton, G Rao, JC Reader Frontiers in Pharmacology 11, 1233, 2020 | 10 | 2020 |
| Randomised phase II trial of weekly ixabepilone±biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer DM Roque, ER Siegel, N Buza, S Bellone, DA Silasi, GS Huang, ... British journal of cancer, 1-9, 2022 | 9 | 2022 |
